- Home
- INVH vs KLTOW Comparison
INVH vs KLTOW Comparison
Compare INVH & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | KLTOW |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | N/A |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INVH | KLTOW |
|---|---|---|
| Price | $26.34 | $0.13 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $35.22 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | N/A |
| Earning Date | 10-29-2025 | N/A |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 32.35 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $2,689,621,000.00 | N/A |
| Revenue This Year | $5.69 | N/A |
| Revenue Next Year | $3.21 | N/A |
| P/E Ratio | $27.74 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $26.02 | N/A |
| 52 Week High | $35.80 | N/A |
Technical Indicators
Market Signals| Indicator | INVH | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 44.16 |
| Support Level | $26.02 | $0.13 |
| Resistance Level | $26.85 | $0.15 |
| Average True Range (ATR) | 0.47 | 0.02 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 12.96 | 11.61 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.